Latest News

First single-drug approach anticoagulation therapy shown to be effective in treatment of DVT

31st August 2010

Results of a significant Phase III EINSTEINDVT study, presented at the European Society of Cardiology (ESC) today, confirmed that, for the first time since the introduction of warfarin 55 years ago,1 we have taken a step towards being able to potentially offer an oral single-drug approach as an alternative to traditional standard treatment [a combination of low molecular weight heparin (LMWH) and warfarin] to patients with deep vein thombosis (DVT).

>>more

Sativex® launched in UK for the treatment of spasticity due to Multiple Sclerosis

21st June 2010

Sativex® (delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)), the first cannabinoid medicine derived from whole plant extracts from the cannabis sativa plant, is launched today to treat spasticity associated with Multiple Sclerosis (MS) by Bayer Schering Pharma.

>>more

Bayer Schering Pharma Cuts Price of its Erectile Dysfunction (ED) Drug Levitra® (vardenafil)

1st June 2010

Bayer Schering Pharma (BSP) today announced that it is reducing the price of all doses of Levitra® (vardenafil) in the UK. Levitra® is a PDE-5 inhibitor, a class of oral treatments licensed to treat Erectile Dysfunction (ED).

>>more

First warfarin comparison study to enrol 90% of atrial fibrillation patients with high risk of stroke

27th May 2010

Comparison of five anticoagulation trials for the prevention of stroke in patients with nonvalvular atrial fibrillation (AF) demonstrates that those enrolled on Bayer’s ROCKET AF trial clearly reflects patients most at risk of stroke..

>>more

Only hope for terminal liver cancer patients now lies with new Government

26th May 2010

NICE rejects Bayer’s appeal of their decision not to recommend NHS funding for sorafenib (Nexavar®) in patients with hepatocellular carcinoma (HCC)

>>more

Dr. Jörg Reinhardt appointed new CEO of Bayer HealthCare

21st April 2010

Leadership change effective 15th August, 2010

>>more

Kids celebrate at Thorpe Park as new iPhone game from Bayer goes mobile

19th April 2010

More than 200 people converged on Thorpe Park on Friday for a special event to mark Bayer HealthCare’s World Haemophilia Day, and the launch of a brand new soccer video game, Kid-K Keepy Uppies.

>>more

Men take the lead...in the bedroom at least

16th April 2010

Nation settles for a kiss and a cuddle over sex - While 98 per cent of Brits surveyed1 believe intimacy plays a vital role in a relationship, it’s men who have to take the lead, with 9 in 10 women admitting that they do not initiate physical contact. However, a new survey reveals that the UK is going back to basics when it comes to the bedroom, with two thirds (53 per cent) of people favouring a kiss and cuddle over sex.

>>more

Avelox® (Moxifloxacin) IV Granted UK Licence for the Treatment of Community-Acquired Pneumonia and Complicated Skin and Skin Structure Infections

10th March 2010

Bayer Schering Pharma is pleased to announce that  Avelox® IV (moxifloxacin HCl, solution for infusion) is now available in the UK for the treatment of Community-Acquired Pneumonia (CAP) and complicated Skin and Skin Structure Infections (cSSSI) when antibacterial agents that are commonly recommended for the initial treatment of these infections are considered inappropriate.

>>more

Final chance for liver cancer patients

22nd February 2010

NICE to hear Bayer’s appeal on the Institute’s decision not to recommend NHS funding for Nexavar® in patients with the most common primary liver cancer.

>>more

NICE recommends all patients admitted to hospital are risk assessed for VTE

27th January 2010

Publication of today’s National Institute for Health and Clinical Excellence’s (NICE) updated Clinical Practice Guideline for prevention of Venous Thromboembolism (VTE) recommends that, for the first time, all patients admitted to hospital are risk assessed for VTE and appropriate measures taken.

>>more

Please note that some links may take you from this Bayer Schering Pharma UK website - marketing authorisations and availability of medicines may differ between the UK and other countries.